Mineralys Therapeutics, Inc.
MLYS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $168,581 | $70,361 | $26,250 | $16,308 |
| G&A Expenses | $23,822 | $14,296 | $5,229 | $2,417 |
| SG&A Expenses | $23,822 | $14,296 | $5,229 | $2,417 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $192,403 | $84,657 | $31,479 | $18,725 |
| Operating Income | -$192,403 | -$84,657 | -$31,479 | -$18,725 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $14,593 | $12,759 | $1,680 | -$683 |
| Pre-Tax Income | -$177,810 | -$71,898 | -$29,799 | -$19,408 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$177,810 | -$71,898 | -$29,799 | -$19,408 |
| % Margin | – | – | – | – |
| EPS | -3.66 | -1.99 | -5.77 | -3.89 |
| % Growth | -83.9% | 65.5% | -48.3% | – |
| EPS Diluted | -3.66 | -1.99 | -5.77 | -3.89 |
| Weighted Avg Shares Out | 48,539 | 36,188 | 5,167 | 4,984 |
| Weighted Avg Shares Out Dil | 48,540 | 36,188 | 5,167 | 4,984 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14,588 | $12,756 | $1,676 | $0 |
| Interest Expense | $0 | $0 | $1,676 | $27 |
| Depreciation & Amortization | $43 | $0 | $0 | $0 |
| EBITDA | -$192,360 | -$84,657 | -$31,479 | -$19,381 |
| % Margin | – | – | – | – |